Monthly Archives: September 2012

The Vision Thing

Putting all of one’s corporate chips on a single therapeutic program is seldom, if ever, a wise strategy. Even if the product moves forward, a company’s longterm viability depends on a periodically replenished pipeline. While this is a well-documented dynamic … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

Still Dead: Bapineuzumab

The press is abuzz with speculation that bapineuzumab might yet have a shot at resurrection, based on subset analyses that showed a slight (9%) difference in amyloid plaque levels in bapi patients, whose levels had appeared to level off, compared … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

What A Long Strange Trip It’s Been: Solanezumab

Alzheimer’s is the major focus of the just-released September issue of NeuroPerspective, and we have already received a number of comments and questions. One of the big questions is –what will come next for solanezumab? This presumes that the release … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment